Literature DB >> 28218486

Determinants and outcomes of upfront surgery versus medical therapy for chronic rhinosinusitis in cystic fibrosis.

Noel Ayoub1, Andrew Thamboo1, Al-Rahim Habib1, Jayakar V Nayak1, Peter H Hwang1.   

Abstract

BACKGROUND: The indications for surgical management of chronic rhinosinusitis (CRS) in patients with cystic fibrosis (CF) are poorly defined. In this study we compare outcomes of medical versus surgical treatment and examine trends associated with the transition from medical to surgical therapy in CF patients.
METHODS: One hundred thirty-six patients with CF referred to a tertiary rhinology practice were retrospectively divided into 3 cohorts: Medical, Upfront Surgery, or Crossover, if they converted from medical to surgical management. The 22-item Sino-Nasal Outcome Test (SNOT-22) and pulmonary function test (PFT) data were assessed up to 48 months.
RESULTS: Compared to patients initially managed medically (n = 90), those who pursued upfront surgery (n = 46) had a greater incidence of nasal polyposis (p = 0.0011), prior sinus surgery (p = 0.0025), lower percent-predicted forced expiratory volume in 1 second (%FEV1 ) (p = 0.0063), and higher Lund-Mackay (p = 0.0025) and SNOT-22 (p = 0.0229) scores. Within the medical group, 35.5% converted to surgery after a mean of 14.3 months. Crossover (n = 32) was associated with a 6.1-point increase in SNOT-22 and a 4.5% deterioration in %FEV1 . Despite worsened symptom severity, the Crossover cohort ultimately achieved similar postoperative SNOT-22 scores (p = 0.831) and %FEV1 (p = 0.114) as those who underwent upfront surgery. Although the Medical cohort had the lowest baseline SNOT-22 scores (p < 0.001), surgery at any time normalized scores to the same baseline level (p = 0.652). Neither medical therapy nor surgery improved PFTs.
CONCLUSIONS: Surgery effectively reduces CRS-related symptoms in CF patients but may not improve pulmonary function. In patients who first pursue medical therapy, symptomatic decline may prompt eventual conversion to surgery. Patients who delay surgery may achieve similar outcomes as those who pursue surgery upfront.
© 2017 ARS-AAOA, LLC.

Entities:  

Keywords:  SNOT-22; chronic rhinosinusitis; cystic fibrosis; endoscopic sinus surgery; medical therapy; pulmonary function

Mesh:

Year:  2017        PMID: 28218486     DOI: 10.1002/alr.21912

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN: 2042-6976            Impact factor:   3.858


  4 in total

1.  Streamlining care in cystic fibrosis: survey of otolaryngologist, pulmonologist, and patient experiences.

Authors:  Zainab Farzal; Kelly M Dean; Satyan B Sreenath; Sarah E Hodge; Brian D Thorp; Charles S Ebert; Adam M Zanation; Brent A Senior; Adam J Kimple
Journal:  Int Forum Allergy Rhinol       Date:  2020-01-17       Impact factor: 3.858

Review 2.  Chronic rhinosinusitis in patients with cystic fibrosis-Current management and new treatments.

Authors:  Brian Jake Johnson; Garret W Choby; Erin K O'Brien
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-06-13

3.  Impact of Cystic Fibrosis Transmembrane Conductance Regulator Therapy on Chronic Rhinosinusitis and Health Status: Deep Learning CT Analysis and Patient-reported Outcomes.

Authors:  Daniel M Beswick; Stephen M Humphries; Connor D Balkissoon; Matthew Strand; Eszter K Vladar; David A Lynch; Jennifer L Taylor-Cousar
Journal:  Ann Am Thorac Soc       Date:  2022-01

4.  Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations.

Authors:  Adam J Kimple; Brent A Senior; Edward T Naureckas; David A Gudis; Ted Meyer; Sarah E Hempstead; Helaine E Resnick; Dana Albon; Wayne Barfield; Margo McKenna Benoit; Daniel M Beswick; Eliza Callard; Shelagh Cofer; Veronica Downer; E Claire Elson; Angela Garinis; Ashleigh Halderman; Lisa Hamburger; Meagan Helmick; Michael McCown; Cameron J McKinzie; Hanna Phan; Kenneth Rodriguez; Ronald C Rubenstein; Ashley Severin; Gopi Shah; Ambika Shenoy; Brittney Sprouse; Frank Virgin; Bradford A Woodworth; Stella E Lee
Journal:  Int Forum Allergy Rhinol       Date:  2022-02-22       Impact factor: 5.426

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.